+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 4985960
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Self-injections Market size was estimated at USD 54.00 billion in 2023, USD 60.64 billion in 2024, and is expected to grow at a CAGR of 12.72% to reach USD 124.87 billion by 2030 .

Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.

Regional Insights

The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.

Type: Rising preference for pen injectors to manage chronic diseases

Auto-injectors are designed for convenient use and can administer a precise dose of medication with minimal training. Auto-injectors are used for the delivery of life-saving drugs in emergencies. The need-based preference for auto-injectors is high among patients who require immediate and reliable administration of drugs, often without the assistance of healthcare professionals. Needle-free injectors offer an alternative to traditional syringe injections, removing the need for needles. Needle-free injectors use a high-pressure, narrow jet of the injection liquid to penetrate the skin to deliver the medication. Individuals with needle phobia mainly prefer needle-free injectors or those who require frequent injections, such as diabetic patients who may otherwise experience needle fatigue. Pen injectors are widely used to manage chronic diseases, allowing insulin or growth hormone self-administration. Pen injectors are portable, discreet, and relatively easy to use, appealing to patients who need to administer medication regularly while maintaining an active lifestyle. Wearable injectors, also known as patch pumps, are devices that adhere to the patient's body and provide continuous or controlled delivery of drugs over an extended period. Wearable injectors are primarily used by patients who require long-term therapies. Auto-injectors and pen injectors are generally favored for their ease of use and reliability. In contrast, needle-free and wearable injectors cater to patients seeking a less invasive or more flexible approach to medication delivery.

Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination

Disposable self-injection devices are single-use injectors preferred for their convenience, safety, and the reduced risk of cross-contamination. Disposable self-injection devices are often chosen by patients requiring short-term medication regimens or those prioritizing the ease of not having to manage the maintenance of the device. Disposable injectors are preferred for diseases with a high risk of infection transmission. Reusable self-injection devices are multi-use systems that offer cost benefits over time and are favored by patients with chronic conditions requiring long-term medication delivery. Reusable self-injection devices are cost-effective, necessitate regular maintenance and are designed for durable use. Reusable injectors are preferred for long-term medication regimens. Disposable injectors offer convenience and safety, especially for patients not requiring long-term medication.

Distribution Channel: Emerging penetration of self-injections on online platforms

Hospital pharmacies primarily serve inpatients and outpatients directly connected to medical facilities. Patients who have been prescribed self-injection therapies during a hospital stay often receive their initial supply of self-injection equipment directly from the hospital pharmacy. Patients requiring specialized instruction on the use of self-injection devices or seeking high-touch support and guidance prefer hospital pharmacies. The rise of eCommerce has extended to the pharmaceutical field, with online pharmacies offering convenience, discretion, and lower prices. Online pharmacies are particularly well-suited for those who are already familiar with their self-injection regimen and prefer home delivery. Patients who prioritize convenience, have mobility and transportation challenges or have a stable self-injection regime choose online pharmacies highly. Private clinics offer personalized care and cater to patients looking for a certain continuity of care with a healthcare provider they trust. Private clinics can be beneficial for receiving self-injection therapies that require consistent monitoring and follow-up with the healthcare practitioner. Hospital pharmacies are preferred for their immediate accessibility and patient education resources, online pharmacies for convenience and potential cost savings, and private clinics for personalized, ongoing care.

Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues

Self-injection therapies are pivotal for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. Biological agents, including adalimumab and etanercept, are administered via self-injection to manage inflammation and modify disease progression. In the management of AIDS, self-injectable formulations of antiretroviral drugs may enhance adherence by providing less frequent dosing options. Self-injectable epinephrine auto-injectors are life-saving devices for individuals with severe allergies. Self-injections allow for immediate treatment in the case of an allergic reaction, preventing potentially fatal anaphylaxis. For oncology patients, self-injectables such as granulocyte colony-stimulating factors (G-CSF) help manage chemotherapy-induced neutropenia. Self-administration can mitigate the need for frequent healthcare visits and support the continuity of cancer treatment. Self-injectable therapies in the treatment of irritable bowel disorders, including Crohn’s disease, involve anti-inflammatory and immunosuppressive drugs, which are vital in controlling symptoms and inducing long-term remission. Self-administered injectable medications, including beta-interferon, are a mainstay in the treatment regimen for multiple sclerosis patients to assist in managing symptoms and slow the progression of the disorder.

In psoriasis, self-injectable biologics target specific pathways within the immune system to reduce the overactive inflammatory response. Self-injectable emergency drugs, designed for rapid administration in crises, include treatments for acute allergic reactions, severe hypoglycemia, and narcotic overdoses, exemplified by epinephrine, glucagon, and naloxone auto-injectors, respectively. Epinephrine auto-injectors are the first line of defense during anaphylactic shocks, a severe, potentially life-threatening allergic reaction. Self-injectable treatments for migraines offer rapid relief of migraine symptoms. Self-injections can abort migraine attacks more quickly than oral medications, which is beneficial for patients with severe symptoms or those experiencing nausea and vomiting. Self-injectables used in hormone replacement therapies provide a consistent delivery method for hormones, including testosterone, estrogen, or progesterone, benefiting patients with hormonal deficiencies or in transgender care. Beta-interferon self-injections are used primarily to treat multiple sclerosis, reduce inflammation, and decrease the frequency of relapse episodes. Erythropoietin (EPO) self-injectables are essential for patients with chronic kidney disease to combat anemia. Erythropoietin (EPO) self-injectables stimulate red blood cell production and help to reduce the need for blood transfusions. Self-injectable follicle-stimulating hormone (FSH) plays a crucial role in fertility treatments. It stimulates ovary follicle growth in women and spermatogenesis in men. Low molecular weight heparin self-injections are commonly used for anticoagulation in patients at risk for thrombosis to provide an easy-to-use option for long-term outpatient anticoagulation therapy. Self-injected insulin is a cornerstone treatment for diabetes management that allows individuals to dose insulin according to their blood glucose levels and dietary intake, providing flexibility and better glycemic control. For osteoporosis patients, self-injected parathyroid hormone can help improve bone density by stimulating new bone growth, an essential aspect of managing severe osteoporosis. Parkinson’s disease patients may benefit from self-injectable medications that can provide symptomatic relief or slow disease progression.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Self-injections Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Self-injections Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Self-injections Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Self-injections Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Self-injections Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Self-injections Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Self-injections Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Self-injections Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Self-injections Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Self-injections Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Self-injections Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Self-injections Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Micron Biomedical Receives Funds To Produce Needle-Free Vaccines

Atlanta-based Micron Biomedical secured a substantial USD 23.6 million investment from the Bill & Melinda Gates Foundation, earmarked for scaling up the production of its revolutionary needle-free vaccines. Employing advanced microarray technology, these vaccines offer a virtually pain-free administration through a simple press of a button. This innovation simplifies the vaccination process and significantly reduces reliance on the cold chain, allowing community health workers to promptly vaccinate children, thereby expanding access to preventive care in low and middle-income regions.

Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval

Enable Injections achieved a significant milestone with the first approval from the U.S. Food and Drug Administration (FDA). The FDA's authorization marks a pivotal step forward for Enable Injections, reinforcing their commitment to advancing self-injection technology, and providing patients with innovative solutions for drug delivery. This approval, detailed in a press release, underscores the company's dedication to quality and safety in developing user-centric devices that simplify the administration of high-volume, subcutaneous injections for various therapies.

Altaviz introduces New Auto-Injector Platform For Drug Delivery

Altaviz's introduced auto-injector platform aids in revolutionizing self-administered medical treatments. This state-of-the-art system is meticulously designed to address various challenges associated with traditional injectable drug delivery, such as improving patient adherence, enhancing ease of use, and minimizing discomfort. By integrating sophisticated technologies, Altaviz's auto-injector offers a highly intuitive solution that empowers patients to manage their treatments effectively and with confidence.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Self-injections Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Auto-Injectors
    • Needle-free Injectors
    • Pen Injectors
    • Wearable Injectors
  • Usage
    • Disposable
    • Reusable
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Private Clinics
  • Therapeutic Areas Application
    • Autoimmune Diseases
      • AIDS
      • Allergies
      • Cancer
      • Irritable Bowel Disorders
      • Multiple Sclerosis
      • Psoriasis
    • Emergency Drugs
      • Anaphylactic Socks
      • Migraine
    • Hormone Replacement Therapies
      • Beta-Interferon
      • Erythropoietin
      • Follicle Stimulating Hormone
      • Heparin
      • Insulin
      • Parathyroid Hormone
      • Parkinson’s
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Self-injections Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
5.1.1.2. Wide availability of self-injections for fertility treatments
5.1.2. Restraints
5.1.2.1. Potential risk of product recall
5.1.3. Opportunities
5.1.3.1. Ongoing government approvals for self-injections worldwide
5.1.3.2. Technological advancements in self-injection devices
5.1.4. Challenges
5.1.4.1. Limited awareness and administration challenges associated with self-injections
5.2. Market Segmentation Analysis
5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
5.3. Market Trend Analysis
5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
5.3.3. Supportive government approvals for self-injections in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Self-injections Market, by Type
6.1. Introduction
6.2. Auto-Injectors
6.3. Needle-free Injectors
6.4. Pen Injectors
6.5. Wearable Injectors
7. Self-injections Market, by Usage
7.1. Introduction
7.2. Disposable
7.3. Reusable
8. Self-injections Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Private Clinics
9. Self-injections Market, by Therapeutic Areas Application
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Emergency Drugs
9.4. Hormone Replacement Therapies
10. Americas Self-injections Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Self-injections Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Self-injections Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. SELF-INJECTIONS MARKET RESEARCH PROCESS
FIGURE 2. SELF-INJECTIONS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SELF-INJECTIONS MARKET DYNAMICS
FIGURE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. SELF-INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. SELF-INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. SELF-INJECTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2018-2023 (USD MILLION)
TABLE 66. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2024-2030 (USD MILLION)
TABLE 67. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 68. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 69. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 70. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 71. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2018-2023 (USD MILLION)
TABLE 72. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2024-2030 (USD MILLION)
TABLE 73. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON’S, BY REGION, 2018-2023 (USD MILLION)
TABLE 74. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON’S, BY REGION, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 79. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 80. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 81. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 82. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 83. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 84. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 85. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 86. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 87. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 88. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 89. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 90. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 91. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 94. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 95. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 96. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 97. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 98. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 99. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 100. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 101. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 102. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 103. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 104. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 105. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 106. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 107. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 108. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 109. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 110. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 111. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 112. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 113. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 114. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 115. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 116. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 117. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 118. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 119. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 120. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 121. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 122. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 123. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 124. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 125. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 126. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 127. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 128. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 129. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 130. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 131. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 132. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 133. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 134. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 135. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 136. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 137. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 138. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 139. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 142. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 143. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 144. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 145. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 146. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 147. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 148. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 149. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 150. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 151. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 152. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 153. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 154. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 155. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 156. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 157. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 158. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 159. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 160. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 161. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 162. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 166. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 168. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 170. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 172. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 174. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 176. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 178. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 179. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 180. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 181. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 182. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 183. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 184. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 185. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 186. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 187. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 188. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 189. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 190. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 191. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 192. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 193. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 194. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 195. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 196. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 197. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 198. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 199. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 200. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 201. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 202. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 203. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 204. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 205. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 206. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 207. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 208. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 209. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 210. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 211. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 212. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 213. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 216. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 217. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 218. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 219. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 220. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 221. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 222. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 223. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 224. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 225. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 226. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 227. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 228. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 229. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 230. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 231. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 232. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 233. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 234. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 235. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 238. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 239. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 240. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 241. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 242. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 243. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 244. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 245. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 246. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 247. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 248. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 249. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 250. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 251. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 252. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 253. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 254. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 255. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 258. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 259. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 260. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 261. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 262. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 263. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 264. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 265. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 266. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 267. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 268. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 269. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 272. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 273. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 274. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 275. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 276. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 277. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 280. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 281. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 282. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 283. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 284. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 285. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 286. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 287. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 288. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 289. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 290. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 291. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 292. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 293. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 294. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 295. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 296. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 297. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 298. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 299. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 300. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 301. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 302. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 303. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 304. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 305. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 306. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 307. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 308. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 309. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 310. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 311. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 312. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 313. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 314. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 315. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 316. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 317. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 318. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 319. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 320. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 321. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 322. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 323. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 324. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 325. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 326. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 327. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 328. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 329. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 330. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
TABLE 331. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
TABLE 332. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
TABLE 333. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 334. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 335. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
TABLE 336. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
TABLE 337. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
TABLE 338. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
TABLE 339. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
TABLE 340. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
TABLE 341. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
TABLE 342. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
TABLE 343. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
TABLE 344. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-203

Companies Mentioned

  • AbbVie Inc.
  • Antares Pharma, Inc. by Halozyme, Inc.
  • AstraZeneca plc
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Credence MedSystems, Inc.
  • DALI Medical Devices Ltd.
  • Eli Lilly and Company
  • Enable Injections, Inc.
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Insulet Corporation
  • Johnson & Johnson Services, Inc.
  • Medmix AG by Sulzer Ltd.
  • Merck KGaA
  • Molex LLC by Koch Industries, Inc.
  • Mylan N.V. by Viatris Inc.
  • Novo Nordisk A/S
  • Owen Mumford Limited
  • PenJet Corporation
  • Pfizer Inc.
  • PharmaJet, Inc.
  • Recipharm AB
  • Sanofi S.A.
  • SCHOTT AG
  • SHL Medical AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.
  • Ypsomed Group

Methodology

Loading
LOADING...

Table Information